

IDERA PHARMACEUTICALS, INC.

Form 4

May 23, 2014

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Abdul-Wahab Umari

2. Issuer Name **and** Ticker or Trading  
Symbol  
IDERA PHARMACEUTICALS,  
INC. [IDRA]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
05/21/2014

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

C/O IDERA  
PHARMACEUTICALS, INC., 167  
SIDNEY STREET

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

CAMBRIDGE, MA 02139

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/21/2014		S		250,000	D	\$ 0	0 <sup>(2)</sup>	I	See Footnotes <sup>(1)</sup> <sup>(2)</sup>
Common Stock	05/22/2014		S		250,000	D	\$ 0	0 <sup>(2)</sup>	I	See Footnotes <sup>(1)</sup> <sup>(2)</sup>
Common Stock	05/23/2014		S		45,000	D	\$ 0	0 <sup>(2)</sup>	I	See Footnotes <sup>(1)</sup> <sup>(2)</sup>

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 4

Common Stock	05/23/2014	X	575,758	A	\$ 0	0 <sup>(3)</sup>	I	See Footnotes <u>(2)</u> <u>(3)</u>
Common Stock	05/23/2014	X	313,341	A	\$ 0	0 <sup>(4)</sup>	I	See Footnotes <u>(2)</u> <u>(4)</u>
Common Stock	05/23/2014	X	110,901	A	\$ 0	0 <sup>(5)</sup>	I	See Footnotes <u>(2)</u> <u>(5)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Warrants	\$ 0.79	05/23/2014		X	575,758	05/07/2013 06/01/2014	Common Stock 575,758
Warrants	\$ 0.79	05/23/2014		X	313,341	05/07/2013 06/01/2014	Common Stock 313,341
Warrants	\$ 0.79	05/23/2014		X	110,901	05/07/2013 06/01/2014	Common Stock 110,901

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Abdul-Wahab Umari C/O IDERA PHARMACEUTICALS, INC. 167 SIDNEY STREET CAMBRIDGE, MA 02139	X

## Signatures

/s/ Abdul-Wahab  
Umari

05/23/2014

\_\_Signature of Reporting  
Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner.

Abdul-Wahab Umari is a director of Pillar GP and serves as the representative of a Pillar I, Pillar II and Pillar GP on the Issuer's board of directors. Mr. Umari disclaims Section 16 beneficial ownership of the Pillar I Warrants, Pillar II Warrants and the Besancon Warrants

(2) (including in each case the common stock underlying such warrants) and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. Umari owns directly 67,304 shares of common stock of the Issuer.

(3) Warrants beneficially owned and exercised for shares of common stock by Pillar I, of which Pillar GP is the general partner (the "Pillar I Warrants").

(4) Warrants beneficially owned and exercised for shares of common stock by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner (the "Pillar II Warrants") of the Issuer.

(5) Warrants beneficially owned and exercised for shares of common stock by Participations Besancon, a fund advised by Pillar GP (the "Besancon Warrants").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.